Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims
Medicaid formulary committees and other gatekeepers face a difficult task. On the one hand they can utilize technical expertise in evaluating the real world evidence for clinical, quality of life and resource utilization claims for competing products while on the other hand they may be asked to ass...
Main Author: | Paul Langley |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2021-02-01
|
Series: | INNOVATIONS in Pharmacy |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/3702 |
Similar Items
-
Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure
by: Paul C Langley
Published: (2016-09-01) -
Modeling Imaginary Worlds: Version 4 of the AMCP Format for Formulary Submissions
by: Paul C Langley
Published: (2016-07-01) -
Next Generation Sequencing Claims in Precision Medicine: Questions a Formulary Committee Should Ask
by: Paul C Langley
Published: (2016-11-01) -
Supporting Formulary Decisions: The Discovery of New Facts or Constructed Evidence?
by: Paul C Langley
Published: (2016-07-01) -
Creative Destruction: Next Generation Sequencing in Drug Development, Formulary Evaluations and Pricing
by: Paul C Langley
Published: (2016-11-01)